Pfizer Inc PFE
News
Pfizer, BioNTech Get Positive CHMP Opinion for New Covid-19 Vaccine
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
Pfizer Declares Third-Quarter 2024 Dividend
Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations
Alnylam's stock surges as heart drug vies with a Pfizer blockbuster
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
Kansas sues Pfizer, saying it misled the public over COVID-19 vaccine
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Pfizer Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2023 — Data Talk
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
Relay Therapeutics to Collaborate with Pfizer to Evaluate Breast Cancer Treatment
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Moderna wins second product approval with RSV vaccine